drugset / Trial / NCT00745199

Evaluating the Effect of Cromolyn Sodium in Uremic Pruritus

NCT00745199

Phase 2 Completed 62 enrolled Shiraz University of Medical Sciences
RandomizedParallel-groupDouble-blindTreatment

Summary

Pruritus is a major disorder among the skin derangements in advanced renal failure. Recent information suggests that interactions between dermal mast cells and distal ends of nonmyelinated C fibers may be important in the precipitation and regulation of the sensory stimuli.Patients having uremic pruritus have been noted to have increased levels of plasma histamine and tryptase as well as increased numbers of dermal mast cells.Cromolyn sodium is a mast cell stabilizing agent that inhibits degranulation of mast cells and the release of histamine, tryptase, and leukotrienes. It is hypothesized that oral cromolyn sodium may attenuate uremic pruritus by decreasing serum tryptase level.

Timeline

Start
2008-05
Primary completion
2008-11
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Cromolyn Small molecule 135 mg Oral